PFE

Pfizer Inc. [PFE] Stock Forecast

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?
RSI : 000

PFE Stock Summary

Top 10 Correlated ETFs

PFE


Top 10 Correlated Stocks

PFE


In the News

10:05 28 Mar 2024 PFE

Is Most-Watched Stock Pfizer Inc. (PFE) Worth Betting on Now?

Pfizer (PFE) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

09:45 28 Mar 2024 PFE

5 Absolutely Best Dividend Stocks Yielding Over 5%

ALERT: 5.25% Yield Is 8x National Average (Sponsored) Robinhood Gold just rolled out a wild 5.25% APY yield for members, a whopping 8x the national average and way better than treasuries.

05:54 28 Mar 2024 PFE

The 2025 Double: 3 Stocks Poised to Deliver 100% Gains in Just 12 Months

Wise investors know that it isn't prudent to chase 100% returns within a period as short as 12 months. Playing the long game is the way to win when investing in the stock market.

01:06 28 Mar 2024 PFE

Harnessing AI for Drug Discovery: Top 3 Stocks to Watch

Artificial intelligence (AI) spans above and beyond today's popular large language models (LLMs). OpenAI's ChatGPT-4 Turbo or even Anthropic's Claude 3 make for an impressive assistant for everyday tasks.

08:22 28 Mar 2024 PFE

One AI/Healthcare Stock to Buy Today

Where to invest today according to our three experts

02:37 28 Mar 2024 PFE

Stock Market Looking Dangerous – 6 Safe Large Cap Dividend Blue Chips

ALERT: Today Could Be Your Best Shot At Early Retirement (Sponsored) If you want to retire before 65, pay attention.

01:05 28 Mar 2024 PFE

Buffett's Backdoor Buys: 3 Stocks His Secret Portfolio Is Quietly Accumulating

Warren Buffett stocks can teach you a thing or two about investing. Warren Buffett's annual shareholders letter to Berkshire Hathaway (NYSE: BRK-A )(NYSE: BRK-B ) investors outlines what he's done the past year and often why.

04:50 28 Mar 2024 PFE

Cathie Wood Is Selling This High-Yield Dividend Stock. Should You?

Cathie Wood's Ark Genomic Innovation ETF has exited its position in Pfizer. Wood is likely disappointed with Pfizer's stock performance and its obesity drug setbacks.

06:45 28 Mar 2024 PFE

Buying These Dirt-Cheap Stocks Could Be a Brilliant Move

Many investors appear to be underestimating Axsome Therapeutics. CRISPR Therapeutics has tremendous long-term prospects.

06:00 28 Mar 2024 PFE

7 Stocks That Will Make Your Friends Green with Envy

There are some stocks to make friends envious for March this year. These companies have impressive growth prospects and strong fundamentals that position them for potential outperformance.

PFE Financial details

Company Rating
Buy
Market Cap
154.5B
Income
2.13B
Revenue
58.5B
Book val./share
15.76
Cash/share
2.25
Dividend
1.65
Dividend %
5.94%
Employees
88K
Optionable
Yes
Shortable
Yes
Earnings
01 May 2024
P/E
73.58
Forward P/E
12.33
PEG
-7.89
P/S
2.68
P/B
1.76
P/C
12.39
P/FCF
32.73
Quick Ratio
0.5
Current Ratio
0.91
Debt / Equity
0.81
LT Debt / Equity
0.69
-
-
EPS (TTM)
0.38
EPS next Y
2.26
EPS next Q
0.55
EPS this Y
-93.2%
EPS next Y
495.29%
EPS next 5Y
638.49%
EPS last 5Y
-33.49%
Revenue last 5Y
2.48%
Revenue Q/Q
7.69%
EPS Q/Q
40.48%
-
-
-
-
SMA20
3.7%
SMA50
-3.45%
SMA100
-9.68%
Inst Own
53.59%
Inst Trans
0.79%
ROA
1%
ROE
2%
ROC
0.02%
Gross Margin
49%
Oper. Margin
6%
Profit Margin
4%
Payout
434%
Shs Outstand
5.65B
Shs Float
5.64B
-
-
-
-
Target Price
52W Range
25.61-42.22
52W High
-33.64%
52W Low
+11.48%
RSI
55
Rel Volume
0.08
Avg Volume
43.78M
Volume
3.42M
Perf Week
0.61%
Perf Month
1.31%
Perf Quarter
-15.88%
Perf Half Y
-15.49%
-
-
-
-
Beta
0.557
-
-
Volatility
0.18%, 0.58%
Prev Close
0.32%
Price
27.87
Change
0.58%

PFE Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2023-12-31

Metric History 2019-12-312020-12-312021-12-312022-12-31 2023-12-31
2.02K2.02K2.02K2.02K2.02K
Revenue per share
9.297.5414.5117.8910.37
Net income per share
2.921.263.925.590.38
Operating cash flow per share
2.262.595.825.221.54
Free cash flow per share
1.792.095.334.640.85
Cash per share
1.772.25.554.052.25
Book value per share
11.3411.3813.7817.0615.77
Tangible book value per share
-5.49-2.620.560.21-7.69
Share holders equity per share
11.3411.3813.7817.0615.77
Interest debt per share
9.657.156.846.4413.25
Market cap
207B204.48B330.74B287.35B162.46B
Enterprise value
257.84B240.97B365.79B321.81B234.65B
P/E ratio
12.7229.1315.059.1676.67
Price to sales ratio
44.884.072.862.78
POCF ratio
16.4414.210.159.8218.67
PFCF ratio
20.7117.6111.0711.0433.9
P/B Ratio
3.283.234.2831.83
PTB ratio
3.283.234.2831.83
EV to sales
4.985.754.53.214.01
Enterprise value over EBITDA
13.0617.1312.827.3722.29
EV to operating cash flow
20.4816.7311.231126.97
EV to free cash flow
25.820.7512.2512.3648.96
Earnings yield
0.080.030.070.110.01
Free cash flow yield
0.050.060.090.090.03
Debt to equity
0.830.610.480.360.81
Debt to assets
0.310.250.20.180.32
Net debt to EBITDA
2.572.591.230.796.86
Current ratio
0.881.351.41.220.91
Interest coverage
9.627.3419.2432.331.79
Income quality
0.772.051.450.934.08
Dividend Yield
0.040.040.030.030.06
Payout ratio
0.491.20.40.294.36
Sales general and administrative to revenue
0.230.230.130.110
Research and developement to revenue
0.170.220.170.110.18
Intangibles to total assets
0.560.510.410.480.59
Capex to operating cash flow
-0.21-0.19-0.08-0.11-0.45
Capex to revenue
-0.05-0.07-0.03-0.03-0.07
Capex to depreciation
-0.43-0.58-0.52-0.64-0.62
Stock based compensation to revenue
0.010.020.010.010.01
Graham number
27.317.9934.8946.3411.54
ROIC
0.120.10.20.270.05
Return on tangible assets
0.220.090.210.310.02
Graham Net
-14.55-11.9-10.11-11.26-19.68
Working capital
-4.5B9.15B17.02B9.12B-4.46B
Tangible asset value
-30.58B-14.58B3.11B1.17B-43.4B
Net current asset value
-71.24B-55.69B-44.32B-50.03B-93.88B
Invested capital
0.830.610.480.360.81
Average receivables
11.73B11.63B13.47B15.14B12.85B
Average payables
4.45B4.26B4.94B6.19B6.76B
Average inventory
7.9B8.16B8.55B9.02B9.59B
Days sales outstanding
85.1297.4970.752.8669.74
Days payables outstanding
150.73180.9566.0672.3683.84
Days of inventory on hand
295.85337.87107.2895.45127.31
Receivables turnover
4.293.745.166.915.23
Payables turnover
2.422.025.535.044.35
Inventory turnover
1.231.083.43.822.87
ROE
0.260.110.280.330.02
Capex per share
-0.47-0.5-0.48-0.58-0.69

Quarterly Fundamentals Overview

Last date of statement is 2023-12-31 for Q4

Metric History 2022-12-312023-04-022023-07-022023-10-01 2023-12-31
2.02K2.02K2.02K2.02K2.02K
Revenue per share
4.333.242.262.342.52
Net income per share
0.890.980.41-0.42-0.59
Operating cash flow per share
1.530.22-0.210.610.93
Free cash flow per share
1.350.01-0.380.470.74
Cash per share
4.053.547.937.832.25
Book value per share
17.0417.9217.5417.1715.76
Tangible book value per share
0.211.381.120.97-7.68
Share holders equity per share
17.0417.9217.5417.1715.76
Interest debt per share
6.276.4311.6611.3912.95
Market cap
287.71B232.97B206.93B191.63B162.58B
Enterprise value
322.17B266.69B269.63B252.07B234.77B
P/E ratio
14.410.5122.23-20.01-12.15
Price to sales ratio
11.8412.7416.2514.4811.41
POCF ratio
33.53192.06-171.1555.4531.03
PFCF ratio
37.953.15K-97.4772.4238.75
P/B Ratio
3.012.312.091.981.83
PTB ratio
3.012.312.091.981.83
EV to sales
13.2614.5921.1719.0516.48
Enterprise value over EBITDA
42.633.8973.85-147.843.05K
EV to operating cash flow
37.54219.86-223.0272.9444.8
EV to free cash flow
42.53.6K-127.0195.2755.95
Earnings yield
0.020.020.01-0.01-0.02
Free cash flow yield
0.030-0.010.010.03
Debt to equity
0.360.360.660.660.81
Debt to assets
0.180.180.30.30.32
Net debt to EBITDA
4.564.2917.18-35.45937.51
Current ratio
1.221.372.122.380.91
Interest coverage
20.5520.074.09-4.7-2.32
Income quality
1.720.22-0.52-1.44-1.57
Dividend Yield
0.010.010.010.010.01
Payout ratio
0.450.420.99-0.97-0.69
Sales general and administrative to revenue
0.080000
Research and developement to revenue
0.150.140.210.20.19
Intangibles to total assets
0.480.480.420.430.59
Capex to operating cash flow
-0.12-0.940.76-0.23-0.2
Capex to revenue
-0.04-0.06-0.07-0.06-0.07
Capex to depreciation
-0.66-0.77-0.58-0.52-0.63
Stock based compensation to revenue
0.010.010.010.010.01
Graham number
18.4619.9212.7512.814.49
ROIC
0.050.040.01-0.01-0.01
Return on tangible assets
0.050.050.02-0.02-0.04
Graham Net
-11.25-10.72-11.2-10.67-19.66
Working capital
9.12B13.52B38.7B42.88B-4.46B
Tangible asset value
1.17B7.76B6.32B5.45B-43.4B
Net current asset value
-50.03B-44.3B-47.53B-43.8B-93.88B
Invested capital
0.360.360.660.660.81
Average receivables
16.57B13.42B11.27B10.66B11.13B
Average payables
6.54B6.47B6.1B5.71B6.02B
Average inventory
9.25B9.26B9.93B10.26B10.2B
Days sales outstanding
53.8360.5872.3175.470.6
Days payables outstanding
63.5291.13119.1145.3170.29
Days of inventory on hand
83.78142201.9486.61106.73
Receivables turnover
1.671.491.241.191.27
Payables turnover
1.420.990.761.991.28
Inventory turnover
1.070.630.451.040.84
ROE
0.050.050.02-0.02-0.04
Capex per share
-0.18-0.2-0.16-0.14-0.18

PFE Frequently Asked Questions

What is Pfizer Inc. stock symbol ?

Pfizer Inc. is a US stock , located in New york of Ny and trading under the symbol PFE

Is Pfizer Inc. buy or a sell ?

31 stock analysts have 31 predictions with a medium analyst target price of $55.98. The lowest prediction is $20 and the highest is $141.39

What is PFE stock prediction ?

With a median analyst target price of $45, 1 stock analysts have made 1 forecasts in last 90 days. $45 is the lowest and $45 is the greatest projection.

What is Pfizer Inc. stock quote today ?

Pfizer Inc. stock price is $27.87 today.

Is Pfizer Inc. stock public?

Yes, Pfizer Inc. is a publicly traded company.

Something similar

Top by Market Cap
Top Correlated ETFs
Top Correlated Stocks